profit from every $100 of sales.
$0$100
Personalis
$15.71-0.95% today
+106.7% in 1 year
1-year low $5.041-year high $18.38
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Personalis sold, what it kept, and what it did with the cash.
Sales went from $65.0 million in 2022 to $69.6 million in 2025, with -$81.3 million of profit last year.
SalesProfit
Personalis vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Personalis | No profit yet | ||
 Illumina | 36.8× · Expensive | ||
 Labcorp Holdings | 34.3× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads Personalis's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 65 | 73 | 85 | 70 | |
| 13 | 18 | 27 | 16 | |
| -116 | -96 | -68 | -88 | |
| -105 | -97 | -70 | -71 | |
| -113 | -108 | -81 | -81 | |
| -2.48 | -2.25 | -1.37 | -0.91 | |
| 20.5% | 24.8% | 31.7% | 22.7% | |
| -177.6% | -131.0% | -80.7% | -126.4% | |
| -174.2% | -147.4% | -96.1% | -116.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 293 | 225 | 270 | 334 |
| Cash | 89 | 57 | 91 | 124 |
| Total debt | 49 | 48 | 44 | 40 |
| Total liabilities | 75 | 96 | 67 | 73 |
| 218 | 129 | 203 | 261 | |
| 46 | 48 | 59 | 89 | |
| -33.5% | -48.2% | -26.0% | -21.3% | |
| -51.9% | -83.7% | -40.0% | -31.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -70 | -56 | -45 | -75 | |
| 50 | 11 | 2 | 5 | |
| -120 | -67 | -47 | -79 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 19 | 14 | 11 | 9 |
Valuation
- –
- –
- –
- 2.7×
- 24.5×
- –
- –
- -4.7%
- -4.8%
- 0.0%
Profitability
- 22.7%
- -126.4%
- -116.7%
- -136.0%
- -35.8%
- -36.4%
- -43.5%
- -29.4%
- -35.8%
- 80.9%
Growth
- +2.3%
- –
- −69.9%
- –
- +19.4%
Financial health
- -1.2×
- 0.12
- 9.5%
- -640.8×
- 6.61
- 6.44
- 0.20
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 12%of 952
Bottom 3%of 884
Bottom 22%of 886
Bottom 19%of 987
What analysts expect
- Average price target
- $11.25
- Range
- $10.00 – $13.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.29 | -0.23 | −26.1% |
| Feb 26, 2026 | -0.26 | -0.31 | +16.1% |
| Nov 4, 2025 | -0.24 | -0.28 | +14.3% |
| Aug 5, 2025 | -0.23 | -0.25 | +8.0% |
| May 6, 2025 | -0.18 | -0.23 | +21.7% |
| Feb 27, 2025 | -0.23 | -0.32 | +28.1% |
| Nov 6, 2024 | -0.64 | -0.33 | −93.9% |
| Aug 7, 2024 | -0.24 | -0.34 | +29.4% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
34No pass
Benjamin Graham
43No pass
Philip Fisher
25No pass
Peter Lynch
31No pass
Joel Greenblatt
0No pass
Charlie Munger
31No pass
Terry Smith
32No pass
Questions about Personalis
Is Personalis a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Personalis AI analysis
What does Personalis do?
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It is in Medical - Diagnostics & Research.
Does Personalis pay a dividend?
No. Personalis does not pay a dividend at the moment.
Is Personalis stock halal?
Yes. Personalis passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
How has Personalis stock done over the past year?
Up 106.7% over the past twelve months, to $15.71. It traded between $5.04 and $18.38 and is 14.5% below its high.
Who are Personalis's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with Personalis's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.